AstraZeneca Suspends Share Buyback Amid Strategy Review

AstraZeneca Plc suspended share buybacks as the board and new Chief Executive Officer Pascal Soriot review strategy at the U.K. drugmaker, prompting renewed speculation that the company will embark on larger takeovers.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.